干扰素治疗HBeAg阴性慢性乙型肝炎临床研究  

A clinical study of the efficacy of a-interferon therapy for HBeAg negative chronic hepatitis B.

作　　者：孙水林[1] 郑晓君[1] 刘朝霞[2] 陈宏义[2] 张俊[2] 陈家鸰[2] 罗杰[1] 

机构地区：[1]江西医学院二附院感染科,江西南昌330006 [2]南昌市第九医院,江西南昌330001

出　　处：《临床肝胆病杂志》2006年第6期427-428,共2页Journal of Clinical Hepatology

基　　金：江西省教育厅基金(2004013)

摘　　要：了解干扰素治疗HBeAg阴性慢性乙型肝炎的疗效。30例HBeAg阴性慢性乙型肝炎患者为治疗组,52例HBeAg阳性慢性乙型肝炎患者为对照组,治疗组及对照组均采用仅干扰素(INFα)6MU隔日一次肌肉注射,疗程24周,观察2组患者治疗前、疗程完成时及之后24周,ALT、HBeAg、HBV-DNA、纤维化四项定量指标。疗程完成后24周,治疗组22人有效,有效率73．3%,高于对照组(x^2=4．267,P＜0．05)；对照组26人有效,有效率50%。治疗组及对照组肝纤维化四项定量指标治疗前后下降明显(P＜0．05)。6MU INFα治疗HBeAg阴性慢性乙型肝炎效果好,较HBeAg阳性慢性乙型肝炎的疗效为优；干扰素能明显阻断或延缓慢性乙型肝炎的肝纤维化。To investigate the effect of α- interferon （INF-α） therapy for HBeAg- negative chronic hepatitis B （CHB）. 30 cases with HBeAg - negative CHB were classified as treated group, while 52 cases with HBeAg - positive chronic hepatitis B as control group. Both groups received injection of INF - α at dose of 6MU every other day for 24 weeks. Levels of alanine aminotransferase, viral markers levels of HBeAg, HBV - DNA and the four serum fibrosis markers were analyzed before and after treatment and 24 weeks after the course. There were 22 cases in treated group and 26 cases in control group who had got obvious therapeutic effects at the end of 24 weeks after treatment. And the rates of efficacy were separately 73.3% and 50%. The rate of treated group was higher than that of control group （x^2 =4. 267 ,P 〈0. 05）. The four serum fibrosis markers of the both groups were clearly dropped after treatment （P 〈0.05）. INF -α at dose of 6MU in treatment for HBeAg - negative CHB is prior to HBeAg - positive CHB. And INF - α have an evident function on preventing or delaying hepatic fibrosis in patients with CHB.

关 键 词：慢性乙型肝炎 HBEAG阴性 干扰素 肝纤维化 

分 类 号：R512.62[医药卫生—内科学]